Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
or

Repligen Corp (RGEN)

Repligen Corp (RGEN)
113.44 +1.50 (+1.34%) 13:11 ET [NASDAQ]
113.16 x 1 113.71 x 33
Realtime by (Cboe BZX)
113.16 x 1 113.71 x 33
Realtime 105.80 -6.14 (-5.49%) 08:30 ET
Quote Overview for Mon, Apr 7th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
104.54
Day High
119.38
Open 105.78
Previous Close 111.94 111.94
Volume 943,298 943,298
Avg Vol 797,878 797,878
Stochastic %K 14.07% 14.07%
Weighted Alpha -35.92 -35.92
5-Day Change -11.92 (-9.37%) -11.92 (-9.37%)
52-Week Range 104.54 - 182.52 104.54 - 182.52
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,285,318
  • Shares Outstanding, K 56,149
  • Annual Sales, $ 634,440 K
  • Annual Income, $ -25,510 K
  • EBIT $ -32 M
  • EBITDA $ 53 M
  • 60-Month Beta 1.27
  • Price/Sales 10.77
  • Price/Cash Flow 39.17
  • Price/Book 3.46

Options Overview Details

View History
  • Implied Volatility 88.19% ( +11.88%)
  • Historical Volatility 64.13%
  • IV Percentile 100%
  • IV Rank 100.00%
  • IV High 88.19% on 04/07/25
  • IV Low 32.53% on 05/17/24
  • Put/Call Vol Ratio 0.50
  • Today's Volume 6
  • Volume Avg (30-Day) 190
  • Put/Call OI Ratio 3.49
  • Today's Open Interest 7,497
  • Open Int (30-Day) 9,358

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 18 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate 0.35
  • Number of Estimates 6
  • High Estimate 0.38
  • Low Estimate 0.32
  • Prior Year 0.28
  • Growth Rate Est. (year over year) +25.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
104.54 +10.31%
on 04/07/25
Period Open: 155.70
153.89 -25.06%
on 03/17/25
-40.38 (-25.93%)
since 03/07/25
3-Month
104.54 +10.31%
on 04/07/25
Period Open: 153.50
182.52 -36.82%
on 01/28/25
-38.18 (-24.87%)
since 01/07/25
52-Week
104.54 +10.31%
on 04/07/25
Period Open: 173.81
182.52 -36.82%
on 01/28/25
-58.49 (-33.65%)
since 04/05/24

Most Recent Stories

More News
Winners And Losers Of Q4: IQVIA (NYSE:IQV) Vs The Rest Of The Drug Development Inputs & Services Stocks

Winners And Losers Of Q4: IQVIA (NYSE:IQV) Vs The Rest Of The Drug Development Inputs & Services Stocks

FTRE : 6.06 (-6.19%)
UFPT : 193.61 (+3.63%)
AZTA : 28.73 (-1.34%)
RGEN : 113.44 (+1.34%)
IQV : 149.77 (-3.21%)
Drug Development Inputs & Services Stocks Q4 In Review: Medpace (NASDAQ:MEDP) Vs Peers

Drug Development Inputs & Services Stocks Q4 In Review: Medpace (NASDAQ:MEDP) Vs Peers

MEDP : 283.26 (-1.34%)
FTRE : 6.06 (-6.19%)
AZTA : 28.73 (-1.34%)
RGEN : 113.44 (+1.34%)
CRL : 132.23 (-3.41%)
Q4 Rundown: PacBio (NASDAQ:PACB) Vs Other Life Sciences Tools & Services Stocks

Q4 Rundown: PacBio (NASDAQ:PACB) Vs Other Life Sciences Tools & Services Stocks

FTRE : 6.06 (-6.19%)
TECH : 51.76 (+0.08%)
PACB : 1.3000 (+5.69%)
RGEN : 113.44 (+1.34%)
MTD : 1,024.14 (+0.14%)
Q4 Earnings Recap: Azenta (NASDAQ:AZTA) Tops Drug Development Inputs & Services Stocks

Q4 Earnings Recap: Azenta (NASDAQ:AZTA) Tops Drug Development Inputs & Services Stocks

FTRE : 6.06 (-6.19%)
UFPT : 193.61 (+3.63%)
AZTA : 28.73 (-1.34%)
RGEN : 113.44 (+1.34%)
WST : 197.70 (-2.71%)
A Look Back at Drug Development Inputs & Services Stocks’ Q4 Earnings: Repligen (NASDAQ:RGEN) Vs The Rest Of The Pack

A Look Back at Drug Development Inputs & Services Stocks’ Q4 Earnings: Repligen (NASDAQ:RGEN) Vs The Rest Of The Pack

FTRE : 6.06 (-6.19%)
MEDP : 283.26 (-1.34%)
RGEN : 113.44 (+1.34%)
AZTA : 28.73 (-1.34%)
IQV : 149.77 (-3.21%)
3 Small-Cap Stocks Skating on Thin Ice

3 Small-Cap Stocks Skating on Thin Ice

RGEN : 113.44 (+1.34%)
ICUI : 140.14 (+0.59%)
DAY : 50.58 (-1.77%)
Repligen Purchases Bioprocessing Analytics Portfolio from 908 Devices

RGEN : 113.44 (+1.34%)
Repligen's Q4 Slightly Tops Expectations

The bioprocessing technology specialist's fourth-quarter results were dragged down by restructuring costs.

RGEN : 113.44 (+1.34%)
Repligen (NASDAQ:RGEN) Posts Q4 Sales In Line With Estimates

Repligen (NASDAQ:RGEN) Posts Q4 Sales In Line With Estimates

RGEN : 113.44 (+1.34%)
Repligen: Q4 Earnings Snapshot

Repligen: Q4 Earnings Snapshot

RGEN : 113.44 (+1.34%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Strengthening short term outlook on maintaining the current direction.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Repligen Corporation is a leading provider of advanced bioprocessing technologies and solutions used by large biopharmaceutical companies and contract manufacturing organizations for manufacturing biologic drugs, such as monoclonal antibodies (mAbs) and gene therapies. Repligen earns revenues from the...

See More

Key Turning Points

3rd Resistance Point 129.63
2nd Resistance Point 124.02
1st Resistance Point 117.98
Last Price 113.44
1st Support Level 106.34
2nd Support Level 100.73
3rd Support Level 94.69

See More

52-Week High 182.52
Fibonacci 61.8% 152.73
Fibonacci 50% 143.53
Fibonacci 38.2% 134.33
Last Price 113.44
52-Week Low 104.54

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Trader's Cheat Sheet: Your Secret Weapon for Smarter Trades